Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 57

Similar articles for PubMed (Select 24959089)

1.

Economic impact of infections among patients with primary immunodeficiency disease receiving IVIG therapy.

Menzin J, Sussman M, Munsell M, Zbrozek A.

Clinicoecon Outcomes Res. 2014 Jun 10;6:297-302. doi: 10.2147/CEOR.S63200. eCollection 2014.

2.

Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.

Simoni-Wastila L, Blanchette CM, Qian J, Yang HW, Zhao L, Zuckerman IH, Pak GH, Silver H, Dalal AA.

Am J Geriatr Pharmacother. 2009 Oct;7(5):262-70. doi: 10.1016/j.amjopharm.2009.11.003.

PMID:
19948302
3.

Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.

Pelletier EM, Ogale S, Yu E, Brunetta P, Garg J.

Clin Ther. 2009 Nov;31(11):2653-64. doi: 10.1016/j.clinthera.2009.11.032.

PMID:
20110008
4.

Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data.

Yu AP, Wu EQ, Birnbaum HG, Emani S, Fay M, Pohl G, Wintle M, Yang E, Oglesby A.

Curr Med Res Opin. 2007 Sep;23(9):2157-69. Review.

PMID:
17669232
5.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
6.

Using intravenous immunoglobulin (IVIG) to treat patients with primary immune deficiency disease.

Bonagura VR.

J Clin Immunol. 2013 Jan;33 Suppl 2:S90-4. doi: 10.1007/s10875-012-9838-1. Epub 2012 Dec 28. Review.

PMID:
23271459
7.

Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting.

Straka RJ, Liu LZ, Girase PS, DeLorenzo A, Chapman RH.

Cardiovasc Diabetol. 2009 Sep 26;8:53. doi: 10.1186/1475-2840-8-53.

8.

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Shepherd J, Jones J, Takeda A, Davidson P, Price A.

Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.

9.

Physiotherapy rehabilitation after total knee or hip replacement: an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2005;5(8):1-91. Epub 2005 Jun 1.

10.

Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency.

Martin A, Lavoie L, Goetghebeur M, Schellenberg R.

Transfus Med. 2013 Feb;23(1):55-60. doi: 10.1111/j.1365-3148.2012.01201.x. Epub 2012 Nov 20.

11.

Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies.

Beauté J, Levy P, Millet V, Debré M, Dudoit Y, Le Mignot L, Tajahmady A, Thomas C, Suarez F, Pellier I, Hermine O, Aladjidi N, Mahlaoui N, Fischer A; French PID study group CEREDIH.

Clin Exp Immunol. 2010 May;160(2):240-5. doi: 10.1111/j.1365-2249.2009.04079.x. Epub 2009 Dec 16.

12.

Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: a resource for economic research.

Pelletier EM, Smith PJ, Boye KS, Misurski DA, Tunis SL, Minshall ME.

Appl Health Econ Health Policy. 2008;6(2-3):103-12. doi: 10.2165/00148365-200806020-00003.

PMID:
19231904
14.

Costs associated with febrile neutropenia in the US.

Michels SL, Barron RL, Reynolds MW, Smoyer Tomic K, Yu J, Lyman GH.

Pharmacoeconomics. 2012 Sep 1;30(9):809-23. doi: 10.2165/11592980-000000000-00000.

PMID:
22804805
15.

Utilization and costs for children who have special health care needs and are enrolled in a hospital-based comprehensive primary care clinic.

Berman S, Rannie M, Moore L, Elias E, Dryer LJ, Jones MD Jr.

Pediatrics. 2005 Jun;115(6):e637-42.

PMID:
15930189
17.

Healthcare utilization and costs of patients with rosacea in an insured population.

Romanowicz M, Stephenson JJ, Del Rosso JQ, Lenhart G.

J Drugs Dermatol. 2008 Jan;7(1):41-9.

PMID:
18246697
18.
19.

Incremental cost burden to US healthcare payers of atrial fibrillation/atrial flutter patients with additional risk factors.

Amin AN, Jhaveri M, Lin J.

Adv Ther. 2011 Oct;28(10):907-26. doi: 10.1007/s12325-011-0065-6. Epub 2011 Sep 30.

PMID:
21971681
20.

One-year follow-up healthcare costs of patients hospitalized for transient ischemic attack or ischemic stroke and discharged with aspirin plus extended-release dipyridamole or clopidogrel.

Burton TM, Lacey M, Liu F, Yu Y, Monsalvo ML, Lang K, Sander S.

J Med Econ. 2012;15(6):1217-25. doi: 10.3111/13696998.2012.718020. Epub 2012 Aug 17.

PMID:
22857539
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk